scispace - formally typeset
G

Ghaleb A. Husseini

Researcher at American University of Sharjah

Publications -  141
Citations -  4742

Ghaleb A. Husseini is an academic researcher from American University of Sharjah. The author has contributed to research in topics: Drug delivery & Nanocarriers. The author has an hindex of 32, co-authored 117 publications receiving 3851 citations. Previous affiliations of Ghaleb A. Husseini include Brigham Young University & Al-Quds University.

Papers
More filters
Journal ArticleDOI

Ultrasonic Drug Delivery – A General Review

TL;DR: There remains a need to better understand the physics of cavitation of microbubbles and the impact that such cavitation has on cells and drug-carrying vesicle and makes cell membranes and capillaries more permeable to drugs.
Journal ArticleDOI

Micelles and nanoparticles for ultrasonic drug and gene delivery

TL;DR: New technologies that combine the use of nanoparticles with acoustic power both in drug and gene delivery both in vitro and in vivo are summarized.
Journal ArticleDOI

The role of cavitation in acoustically activated drug delivery.

TL;DR: This study showed a strong correlation between percent drug release and subharmonic acoustic emissions, and they attribute the drug release to collapse cavitation that perturbs the structure of the micelle and releases drug.
Journal ArticleDOI

Factors affecting acoustically triggered release of drugs from polymeric micelles

TL;DR: Data suggest an important role of transient cavitation in drug release, which suggests that upon leaving the sonicated volume, the non-extravasated and non-internalized drug would circulate in the encapsulated form, thus preventing unwanted drug interactions with normal tissues.
Journal ArticleDOI

Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake

TL;DR: The effect of high-frequency ultrasound on doxorubicin (DOX) release from Pluronic micelles and intracellular DOX uptake was studied for promyelocytic leukemia HL-60 cells, ovarian carcinoma drug-sensitive and multidrug-resistant (MDR) cells, and breast cancer MCF-7 cells.